Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
Oncolytics Biotech (NASDAQ: ONCY) hosted a key opinion leader (KOL) webinar focusing on pelareorep's clinical data in pancreatic and gastrointestinal cancers. The event highlighted significant survival benefits demonstrated by pelareorep-based combinations in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) patients.
Key findings show that pelareorep combined with chemotherapy represents a promising treatment option for mPDAC patients. Translational data from multiple clinical trials validated pelareorep's mechanism of action, demonstrating tumor replication, chemokine expression stimulation, and correlation between tumor-infiltrating lymphocytes expansion and tumor size reduction.
Oncolytics Biotech (NASDAQ: ONCY) ha organizzato un webinar con leader di opinione chiave (KOL) incentrato sui dati clinici di pelareorep nei tumori pancreatici e gastrointestinali. L'evento ha messo in evidenza i significativi benefici di sopravvivenza dimostrati dalle combinazioni a base di pelareorep nei pazienti con adenocarcinoma duttale pancreatico metastatico (mPDAC) in prima linea.
I risultati principali mostrano che pelareorep associato alla chemioterapia rappresenta un'opzione terapeutica promettente per i pazienti con mPDAC. I dati traslazionali provenienti da diversi studi clinici hanno confermato il meccanismo d'azione di pelareorep, evidenziando la replicazione tumorale, la stimolazione dell'espressione di chemochine e la correlazione tra l'espansione dei linfociti infiltranti il tumore e la riduzione delle dimensioni tumorali.
Oncolytics Biotech (NASDAQ: ONCY) organiz贸 un seminario web con l铆deres de opini贸n clave (KOL) centrado en los datos cl铆nicos de pelareorep en c谩nceres pancre谩ticos y gastrointestinales. El evento destac贸 los significativos beneficios de supervivencia demostrados por las combinaciones basadas en pelareorep en pacientes con adenocarcinoma ductal pancre谩tico metast谩sico (mPDAC) de primera l铆nea.
Los hallazgos clave muestran que pelareorep combinado con quimioterapia representa una opci贸n de tratamiento prometedora para pacientes con mPDAC. Los datos traslacionales de m煤ltiples ensayos cl铆nicos validaron el mecanismo de acci贸n de pelareorep, demostrando replicaci贸n tumoral, estimulaci贸n de la expresi贸n de quimiocinas y correlaci贸n entre la expansi贸n de linfocitos infiltrantes del tumor y la reducci贸n del tama帽o tumoral.
Oncolytics Biotech (NASDAQ: ONCY)電� 旆岇灔 氚� 鞙勳灔甏� 鞎旍棎靹� 韼犽澕霠堨槫霠欖潣 鞛勳儊 雿办澊韯半ゼ 欷戩嫭鞙茧 頃� 欤检殧 鞚橁铂 毽崝(KOL) 鞗箘雮橂ゼ 臧滌禍頄堨姷雼堧嫟. 鞚措矆 頄夓偓鞐愳劀電� 1彀� 鞝勳澊靹� 旆岅磤 靹犾晹(mPDAC) 頇橃瀽鞐愳劀 韼犽澕霠堨槫霠� 旮半皹 氤戩毄鞖旊矔鞚� 氤挫棳欷� 鞙犾潣氙疙暅 靸濎〈 鞚挫爯鞚� 臧曥“頄堨姷雼堧嫟.
欤检殧 瓴瓣臣電� 韼犽澕霠堨槫霠欔臣 頇旐暀鞖旊矔鞚� 氤戩毄鞚� mPDAC 頇橃瀽鞐愱矊 鞙犽頃� 旃橂 鞓奠厴鞛勳潉 氤挫棳欷嶋媹雼�. 鞐煬 鞛勳儊鞁滍棙鞐愳劀 鞏混潃 鞝勳澊 鞐瓣惮 雿办澊韯�電� 韼犽澕霠堨槫霠欖潣 鞛戩毄 旮办爠鞚� 鞛呾頄堨溂氅�, 膦呾枒 氤奠牅, 旒�氇勾鞚� 氚滍槃 鞛愱饭, 膦呾枒 旃湦 毽柬攧甑� 頇曥灔瓿� 膦呾枒 韥赴 臧愳唽 臧勳潣 靸侁磤甏�瓿勲ゼ 雮橅儉雰堨姷雼堧嫟.
Oncolytics Biotech (NASDAQ : ONCY) a organis茅 un webinaire avec des leaders d'opinion cl茅s (KOL) ax茅 sur les donn茅es cliniques de pelareorep dans les cancers du pancr茅as et gastro-intestinaux. L'茅v茅nement a mis en lumi猫re les avantages significatifs en termes de survie d茅montr茅s par les combinaisons 脿 base de pelareorep chez les patients atteints d'ad茅nocarcinome canalaire pancr茅atique m茅tastatique (mPDAC) en premi猫re ligne.
Les r茅sultats cl茅s montrent que pelareorep associ茅 脿 la chimioth茅rapie repr茅sente une option th茅rapeutique prometteuse pour les patients atteints de mPDAC. Les donn茅es translationnelles issues de plusieurs essais cliniques ont valid茅 le m茅canisme d'action de pelareorep, d茅montrant la r茅plication tumorale, la stimulation de l'expression des chimiokines et la corr茅lation entre l'expansion des lymphocytes infiltrant la tumeur et la r茅duction de la taille tumorale.
Oncolytics Biotech (NASDAQ: ONCY) veranstaltete ein Webinar mit Meinungsf眉hrern (KOL), das sich auf die klinischen Daten von Pelareorep bei Pankreas- und gastrointestinalen Krebserkrankungen konzentrierte. Die Veranstaltung hob die signifikanten 脺berlebensvorteile hervor, die durch pelareorep-basierte Kombinationen bei Patienten mit metastasiertem duktalem Pankreasadenokarzinom (mPDAC) in der Erstlinie nachgewiesen wurden.
Wichtige Erkenntnisse zeigen, dass Pelareorep in Kombination mit Chemotherapie eine vielversprechende Behandlungsoption f眉r mPDAC-Patienten darstellt. Translationalen Daten aus mehreren klinischen Studien best盲tigten den Wirkmechanismus von Pelareorep, indem sie Tumorreplikation, Stimulation der Chemokin-Expression und eine Korrelation zwischen der Ausweitung tumorinfiltrierender Lymphozyten und der Tumorgr枚脽e zeigten.
- Demonstrated meaningful survival benefit in first-line mPDAC patients across multiple studies
- Validated mechanism of action through translational data from multiple clinical trials
- Potential opportunity in untapped immunotherapy market for mPDAC treatment
- Strong positioning for combination strategies and partnerships in GI oncology
- Still requires a registration-enabling study before potential approval
- Faces potential competition from emerging RAS inhibitors in the treatment landscape
Insights
Pelareorep shows promising survival benefits in pancreatic cancer with clear development pathway toward registration trials.
The KOL event for Oncolytics Biotech presents compelling evidence for pelareorep's potential in treating metastatic pancreatic ductal adenocarcinoma (mPDAC), one of the most challenging cancer types with dismal survival rates. Most notably, the drug has demonstrated meaningful survival benefits in first-line metastatic pancreatic cancer patients across multiple clinical studies, which justifies advancement to registration-enabling trials - the final step before potential FDA approval.
What makes pelareorep particularly interesting is its immunotherapeutic mechanism. The translational data confirms that pelareorep successfully replicates within tumors, stimulates chemokine expression, and induces expansion of tumor-infiltrating lymphocytes (TILs) that correlates with tumor size reduction. This is significant because immunotherapies have yet to be approved for mPDAC, representing a substantial unmet need and market opportunity.
The KOLs' assessment that pelareorep combined with chemotherapy would remain appealing even with RAS inhibitors in the treatment landscape suggests the drug has a differentiated position that could withstand competitive pressures. For Oncolytics, this positions pelareorep as an attractive asset for potential pharmaceutical partnerships, particularly for companies looking to establish or expand their oncology presence in the gastrointestinal cancer space. The company's dual strategy of pursuing registration development while engaging potential partners maximizes optionality for bringing this therapy to market.
A selection of key takeaways includes:
- The meaningful survival benefit demonstrated by聽pelareorep-based treatment combinations in first-line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC) patients across randomized and single-arm clinical studies necessitates evaluating pelareorep in a registration-enabling study in 1L mPDAC.
- Immunotherapies have not yet been approved to treat mPDAC patients, illustrating an unmet need, which provides an opportunity for an immunologically active agent like pelareorep to deliver an impactful clinical benefit in this challenging indication.
- The combination of聽pelareorep and chemotherapy would be an appealing treatment option for 1L mPDAC patients, even with the presence of RAS inhibitors in the treatment paradigm.
- Translational data from multiple聽mPDAC and colorectal cancer clinical trials validate pelareorep's mechanism of action, showing that it replicates in tumors, stimulates chemokine expression, and induces the expansion of tumor-infiltrating lymphocytes (TILs), which correlates with a reduction in tumor size.
"I want to thank our esteemed panel of oncologists for their meaningful contributions to our KOL event," said Jared Kelly, Chief Executive Officer of Oncolytics. "Their insights underscore a critical and timely message: pelareorep is a compelling immunotherapy platform that is well situated for combination strategies and a highly differentiated asset for pharma partners looking to expand or establish leadership in GI oncology. We are committed to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers."
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot"聽-- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit:聽聽or follow the company on social media on 聽and on X @.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our commitment to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers; our plans to advance pelareorep into registration enabling studies in metastatic breast cancer and pancreatic cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and
Company Contact
Jon Patton
Director of IR & Communication
[email protected]
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
[email protected]
Media Contact for Oncolytics
Owen Blaschak
LifeSci Communications
[email protected]
Logo -
View original content to download multimedia:
SOURCE Oncolytics Biotech庐 Inc.
FAQ
What were the key findings from ONCY's KOL event about pelareorep?
How does pelareorep work in treating pancreatic cancer?
What is the market opportunity for ONCY's pelareorep in pancreatic cancer?
What are the next steps for ONCY's pelareorep development?
How does pelareorep fit into the current pancreatic cancer treatment landscape?
